5-ethyl-2,4-dihydroxybenzoic acid hydrazide | 888216-43-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-ethyl-2,4-dihydroxybenzoic acid hydrazide
• 英文别名: 5-Ethyl-2,4-dihydroxybenzohydrazide
• CAS: 888216-43-1
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: AKZGWPYLIJVFMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  95.6
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-isothiocyanato-4-methoxynaphthalene 、 5-ethyl-2,4-dihydroxybenzoic acid hydrazide 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 3-(2,4-dihydroxy-5-ethylphenyl)-4-(4-methoxynaphthalen-1-yl)-5-mercapto-[1,2,4]triazole
  参考文献：
  名称：

  Method for treating proliferative disorders associated with mutations in c-Met

  摘要：

  本发明涉及在需要的人体中抑制Hsp90活性的方法，以及治疗需要的人体中与c-Met相关的癌症的方法。

  公开号：

  US09108933B2

文献信息

• Method for treating proliferative disorders associated with protooncogene products
  申请人：Du Zhenjian

  公开号：US20080004266A1

  公开（公告）日：2008-01-03

  The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

  本发明涉及抑制Hsp90在需要的受试者中的活性的方法，以及治疗Bcr-Abl、FLT-3、EGFR、c-Kit、B-raf和NPM-ALK相关癌症的方法，适用于需要的受试者。
• Triazole compounds that modulate Hsp90 activity
  申请人：Ying Weiwen

  公开号：US20060167070A1

  公开（公告）日：2006-07-27

  The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

  本发明涉及取代的三唑化合物和包含取代的三唑化合物的组合物。本发明还涉及在需要的主体中抑制Hsp90活性的方法以及预防或治疗过度增殖性疾病，如癌症，的方法，包括向该主体给予本发明的取代三唑化合物或含有这种化合物的组合物。
• Triazole compounds that modulate HSP90 activity
  申请人：Ying Weiwen

  公开号：US20080090887A1

  公开（公告）日：2008-04-17

  The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

  本发明涉及替代三唑化合物和包含替代三唑化合物的组合物。本发明还涉及一种在需要的主体中抑制Hsp90活性的方法，以及用于预防或治疗过度增殖性疾病（如癌症）的方法，包括向该主体施用本发明的替代三唑化合物或含有这种化合物的组合物。
• TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
  申请人：Ying Weiwen

  公开号：US20100093717A1

  公开（公告）日：2010-04-15

  The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of treating or inhibiting angiogenesis in a subject in need thereof and methods for blocking, occluding, or otherwise disrupting blood flow in neo vasculature, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

  本发明涉及取代的三唑化合物和包含取代的三唑化合物的组合物。本发明还涉及治疗或抑制需要的受体中的血管生成的方法，以及用于阻塞、闭塞或以其他方式破坏新生血管中的血流的方法，包括向受体中给予本发明的取代三唑化合物或包含这种化合物的组合物。
• Method for treating non-hodgkin's lymphoma
  申请人：Foley Kevin

  公开号：US20080004276A1

  公开（公告）日：2008-01-03

  The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating non-Hodgkin's lymphoma, in a subject in need thereof.

  本发明涉及抑制Hsp90在需要的受体中的活性的方法，以及用于治疗需要的非霍奇金淋巴瘤的方法。